The UK government has announced new incentives to boost investment in the pharmaceutical sector, as part of a drive to strengthen the country’s life sciences industry post-Brexit.
Under the new strategy, global pharmaceutical firms will be offered streamlined regulatory pathways and tax incentives to establish or expand operations in the UK. The initiative builds on the 2021 Life Sciences Vision and aims to secure the UK’s position as a global hub for innovation.
Health Secretary Wes Streeting said, “We want the UK to be the best place in the world to research, develop, and manufacture medicines. Our NHS provides the ideal testing ground for innovation that benefits patients globally.”
The plan also includes increased funding for clinical trials and closer collaboration between universities, biotech startups, and the NHS.
Investing in pharmaceutical innovation benefits everyone — from patients awaiting breakthrough treatments to healthcare workers striving for better outcomes. However, it must go hand in hand with affordability and accessibility to ensure progress serves all.
